Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study
Oral ulcers, the hallmark of Behçet's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed. Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways. We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behçet's syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks. This regimen was followed by a 12-week extension phase in which the placebo group was switched to apremilast and a 28-day post-treatment observational follow-up phase. The patients and clinicians were unaware of the study assignments throughout the trial. The primary end point was the number of oral ulcers at week 12. Secondary outcomes included pain from these ulcers (measured on a 100-mm visual-analogue scale, with higher scores indicating worse pain), the number of genital ulcers, overall disease activity, and quality of life. The mean (±SD) number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group (0.5±1.0 vs. 2.1±2.6) (P<0.001). The mean decline in pain from oral ulcers from baseline to week 12 was greater with apremilast than with placebo (-44.7±24.3 mm vs. -16.0±32.5 mm) (P<0.001). Nausea, vomiting, and diarrhea were more common in the apremilast group (with 22, 9, and 12 incidents, respectively, among 55 patients) than in the placebo group (with 10, 1, and 2 incidents, respectively, among 56 patients), findings that were similar to those in previous studies of apremilast. There were two serious adverse events in patients receiving apremilast. Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Behçet's syndrome. This preliminary study was neither large enough nor long enough to assess long-term efficacy, the effect on other manifestations of Behçet's syndrome, or the risk of uncommon serious adverse events. (Funded by Celgene; ClinicalTrials.gov number, NCT00866359.)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:372 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 372(2015), 16, Seite 1510 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hatemi, Gulen [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1968368639 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1968368639 | ||
| 003 | DE-627 | ||
| 005 | 20220223153650.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1968368639 | ||
| 035 | |a (DE-599)GBVOLC1968368639 | ||
| 035 | |a (PRQ)g1826-20753cc682c87d767275c53b0ab6136f1d93f058c36d68600fd801d762f274cb0 | ||
| 035 | |a (KEY)0171808820150000372001601510apremilastforbehetssyndromeaphase2placebocontrolle | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Hatemi, Gulen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Oral ulcers, the hallmark of Behçet's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed. Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways. We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behçet's syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks. This regimen was followed by a 12-week extension phase in which the placebo group was switched to apremilast and a 28-day post-treatment observational follow-up phase. The patients and clinicians were unaware of the study assignments throughout the trial. The primary end point was the number of oral ulcers at week 12. Secondary outcomes included pain from these ulcers (measured on a 100-mm visual-analogue scale, with higher scores indicating worse pain), the number of genital ulcers, overall disease activity, and quality of life. The mean (±SD) number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group (0.5±1.0 vs. 2.1±2.6) (P<0.001). The mean decline in pain from oral ulcers from baseline to week 12 was greater with apremilast than with placebo (-44.7±24.3 mm vs. -16.0±32.5 mm) (P<0.001). Nausea, vomiting, and diarrhea were more common in the apremilast group (with 22, 9, and 12 incidents, respectively, among 55 patients) than in the placebo group (with 10, 1, and 2 incidents, respectively, among 56 patients), findings that were similar to those in previous studies of apremilast. There were two serious adverse events in patients receiving apremilast. Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Behçet's syndrome. This preliminary study was neither large enough nor long enough to assess long-term efficacy, the effect on other manifestations of Behçet's syndrome, or the risk of uncommon serious adverse events. (Funded by Celgene; ClinicalTrials.gov number, NCT00866359.). | ||
| 650 | 4 | |a Genital Diseases, Male - drug therapy | |
| 650 | 4 | |a Behcet Syndrome - complications | |
| 650 | 4 | |a Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | |
| 650 | 4 | |a Genital Diseases, Female - drug therapy | |
| 650 | 4 | |a Behcet Syndrome - drug therapy | |
| 650 | 4 | |a Oral Ulcer - drug therapy | |
| 650 | 4 | |a Thalidomide - analogs & derivatives | |
| 650 | 4 | |a Oral Ulcer - etiology | |
| 650 | 4 | |a Phosphodiesterase 4 Inhibitors - therapeutic use | |
| 650 | 4 | |a Thalidomide - therapeutic use | |
| 650 | 4 | |a Anti-Inflammatory Agents, Non-Steroidal - adverse effects | |
| 650 | 4 | |a Thalidomide - adverse effects | |
| 650 | 4 | |a Phosphodiesterase 4 Inhibitors - adverse effects | |
| 650 | 4 | |a Vomiting | |
| 650 | 4 | |a Behcet's disease | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Care and treatment | |
| 650 | 4 | |a Nausea | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Usage | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Inhibitor drugs | |
| 650 | 4 | |a Ulcers | |
| 650 | 4 | |a Medical research | |
| 650 | 4 | |a Drug therapy | |
| 700 | 1 | |a Melikoglu, Melike |4 oth | |
| 700 | 1 | |a Tunc, Recep |4 oth | |
| 700 | 1 | |a Korkmaz, Cengiz |4 oth | |
| 700 | 1 | |a Turgut Ozturk, Banu |4 oth | |
| 700 | 1 | |a Mat, Cem |4 oth | |
| 700 | 1 | |a Merkel, Peter A |4 oth | |
| 700 | 1 | |a Calamia, Kenneth T |4 oth | |
| 700 | 1 | |a Liu, Ziqi |4 oth | |
| 700 | 1 | |a Pineda, Lilia |4 oth | |
| 700 | 1 | |a Stevens, Randall M |4 oth | |
| 700 | 1 | |a Yazici, Hasan |4 oth | |
| 700 | 1 | |a Yazici, Yusuf |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 372(2015), 16, Seite 1510 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:372 |g year:2015 |g number:16 |g pages:1510 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25875256 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1673854498 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_287 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2012 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 372 |j 2015 |e 16 |h 1510 | ||